BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Boston - ECPv6.17.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://scienceinboston.com
X-WR-CALDESC:Events for Science in Boston
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210729T170000
DTEND;TZID=America/Toronto:20210729T180000
DTSTAMP:20210726T191346Z
CREATED:20210726T191126Z
LAST-MODIFIED:20210726T191346Z
UID:15681-1627578000-1627581600@scienceinboston.com
SUMMARY:Genomics\, COVID-19\, and Us: Understanding Variants’ Spread\, and Our Susceptibility to Disease
DESCRIPTION:Science For All Seasons: Genomics\, COVID-19\, and us: Understanding variants’ spread\, and our susceptibility to disease\n\n  \nTo understand and control COVID-19\, we need to look at the genome of the virus that causes it\, as well as our own. Human geneticist Benjamin Neale will discuss the emerging understanding of how our DNA influences our body’s response to the virus\, and viral geneticist Bronwyn MacInnis will talk about what the growing science of genomic epidemiology continues to teach us about the evolution and spread of viral variants. \nThis lecture is presented in memory of Eliana Hechter and is supported by the Eliana Hechter Memorial Fund.
URL:https://scienceinboston.com/event/genomics-covid-19-and-us-understanding-variants-spread-and-our-susceptibility-to-disease/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinboston.com/wp-content/uploads/sites/6/2021/07/science-for-all-seasons.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210729T170000
DTEND;TZID=America/Toronto:20210729T180000
DTSTAMP:20210726T191126Z
CREATED:20210726T191126Z
LAST-MODIFIED:20210726T191126Z
UID:27733-1627578000-1627581600@scienceinboston.com
SUMMARY:Genomics\, COVID-19\, and Us: Understanding Variants’ Spread\, and Our Susceptibility to Disease
DESCRIPTION:Science For All Seasons: Genomics\, COVID-19\, and us: Understanding variants’ spread\, and our susceptibility to disease\n\n  \nTo understand and control COVID-19\, we need to look at the genome of the virus that causes it\, as well as our own. Human geneticist Benjamin Neale will discuss the emerging understanding of how our DNA influences our body’s response to the virus\, and viral geneticist Bronwyn MacInnis will talk about what the growing science of genomic epidemiology continues to teach us about the evolution and spread of viral variants. \nThis lecture is presented in memory of Eliana Hechter and is supported by the Eliana Hechter Memorial Fund.
URL:https://scienceinboston.com/event/genomics-covid-19-and-us-understanding-variants-spread-and-our-susceptibility-to-disease-2/
LOCATION:Online
ATTACH;FMTTYPE=image/png:https://scienceinboston.com/wp-content/uploads/sites/6/2021/07/science-for-all-seasons.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210812T200000
DTEND;TZID=America/Toronto:20210812T210000
DTSTAMP:20210726T205200Z
CREATED:20210726T205200Z
LAST-MODIFIED:20210726T205200Z
UID:15704-1628798400-1628802000@scienceinboston.com
SUMMARY:Financing Life Science Ventures - What it Means to Founders and Investors
DESCRIPTION:The COVID-19 pandemic has made 2020 a transformational year for the life science industry\, creating vast opportunities to drive innovation forward. What does this mean to founders and funders to capture the growth? What to look for and look out for? \nOur panelists\, Philip Crowley (Crowley Law LLC) and Daniel Oliver (MBA ’13\, CEO & Co-founder Rejuvenate Bio) have years of industry experience and will discuss some of the unique obstacles and challenges entrepreneurs and Angel investors face in dealing with early-stage financing – and some potential solutions.  The discussion will be moderated by Sheila Sun (MBA ’13).
URL:https://scienceinboston.com/event/financing-life-science-ventures-what-it-means-to-founders-and-investors/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210812T200000
DTEND;TZID=America/Toronto:20210812T210000
DTSTAMP:20210726T205200Z
CREATED:20210726T205200Z
LAST-MODIFIED:20210726T205200Z
UID:27734-1628798400-1628802000@scienceinboston.com
SUMMARY:Financing Life Science Ventures - What it Means to Founders and Investors
DESCRIPTION:The COVID-19 pandemic has made 2020 a transformational year for the life science industry\, creating vast opportunities to drive innovation forward. What does this mean to founders and funders to capture the growth? What to look for and look out for? \nOur panelists\, Philip Crowley (Crowley Law LLC) and Daniel Oliver (MBA ’13\, CEO & Co-founder Rejuvenate Bio) have years of industry experience and will discuss some of the unique obstacles and challenges entrepreneurs and Angel investors face in dealing with early-stage financing – and some potential solutions.  The discussion will be moderated by Sheila Sun (MBA ’13).
URL:https://scienceinboston.com/event/financing-life-science-ventures-what-it-means-to-founders-and-investors-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210818T090000
DTEND;TZID=America/Toronto:20210818T100000
DTSTAMP:20210816T202916Z
CREATED:20210816T202916Z
LAST-MODIFIED:20210816T202916Z
UID:15997-1629277200-1629280800@scienceinboston.com
SUMMARY:Microglia and Myelin: Improved Tools for Their Study and Molecular Interactions Between Them
DESCRIPTION:Join via Zoom: https://mit.zoom.us/j/99379257055?pwd=QW40ajU5V0NFL1gxUkI4OFhlSzJzUT09  \nPassword: microglia \n  \nAbstract: Myelination of axons evolved in vertebrates to promote signal transduction and the development of a compact and energy-efficient nervous system. Myelin development and homeostasis are critical for normal function and impairment of myelin is associated with sensory\, motor\, and cognitive dysfunction. While it has long been understood that oligodendrocytes produce myelin in the CNS\, more recent studies also implicate additional cell types including microglia as providers of important molecular cues in myelination. However\, the function of many molecular mediators remains incompletely defined\, at least in part due to the scarcity of suitable tools. In this thesis\, we develop and provide the research community with much needed new tools to study microglia and myelin and dissect the contribution of IgG to myelin development. In Chapter 1\, we report the generation and characterization of now widely adopted EGFP and CreERT2 transgenic mouse lines for the labeling and the inducible genetic manipulation of microglia. Extending this work\, in Chapter 2\, we present evidence for the engineering of a highly efficient and specific constitutively active Cre line leveraging the Fcrls locus. In Chapter 3\, we report the development of MyelTracer\, an easy-to-install software suite made available to the research community for the quantification of myelin g-ratio\, a key metric in studies of myelin morphology. Finally\, in Chapter 4\, we present evidence for the occurrence of maternally derived IgG on microglia in the postnatal brain and show that brains of mice lacking IgG postnatally display oligodendroglial and axonal abnormalities. Further\, we show that this effect of IgG is not mediated through the canonical IgG-Fc receptor pathway. Independent of Fc receptors\, IgG appears to be required for the function of a subset of microglia that occurs in white-matter tracts postnatally and is required for normal white-matter development. Overall\, the work presented in this thesis resulted in the generation of several much-needed tools for the research community\, and it reveals molecular insights into the role of IgG in the developing brain.
URL:https://scienceinboston.com/event/microglia-and-myelin-improved-tools-for-their-study-and-molecular-interactions-between-them/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210818T090000
DTEND;TZID=America/Toronto:20210818T100000
DTSTAMP:20210816T202916Z
CREATED:20210816T202916Z
LAST-MODIFIED:20210816T202916Z
UID:27738-1629277200-1629280800@scienceinboston.com
SUMMARY:Microglia and Myelin: Improved Tools for Their Study and Molecular Interactions Between Them
DESCRIPTION:Join via Zoom: https://mit.zoom.us/j/99379257055?pwd=QW40ajU5V0NFL1gxUkI4OFhlSzJzUT09  \nPassword: microglia \n  \nAbstract: Myelination of axons evolved in vertebrates to promote signal transduction and the development of a compact and energy-efficient nervous system. Myelin development and homeostasis are critical for normal function and impairment of myelin is associated with sensory\, motor\, and cognitive dysfunction. While it has long been understood that oligodendrocytes produce myelin in the CNS\, more recent studies also implicate additional cell types including microglia as providers of important molecular cues in myelination. However\, the function of many molecular mediators remains incompletely defined\, at least in part due to the scarcity of suitable tools. In this thesis\, we develop and provide the research community with much needed new tools to study microglia and myelin and dissect the contribution of IgG to myelin development. In Chapter 1\, we report the generation and characterization of now widely adopted EGFP and CreERT2 transgenic mouse lines for the labeling and the inducible genetic manipulation of microglia. Extending this work\, in Chapter 2\, we present evidence for the engineering of a highly efficient and specific constitutively active Cre line leveraging the Fcrls locus. In Chapter 3\, we report the development of MyelTracer\, an easy-to-install software suite made available to the research community for the quantification of myelin g-ratio\, a key metric in studies of myelin morphology. Finally\, in Chapter 4\, we present evidence for the occurrence of maternally derived IgG on microglia in the postnatal brain and show that brains of mice lacking IgG postnatally display oligodendroglial and axonal abnormalities. Further\, we show that this effect of IgG is not mediated through the canonical IgG-Fc receptor pathway. Independent of Fc receptors\, IgG appears to be required for the function of a subset of microglia that occurs in white-matter tracts postnatally and is required for normal white-matter development. Overall\, the work presented in this thesis resulted in the generation of several much-needed tools for the research community\, and it reveals molecular insights into the role of IgG in the developing brain.
URL:https://scienceinboston.com/event/microglia-and-myelin-improved-tools-for-their-study-and-molecular-interactions-between-them-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210818T120000
DTEND;TZID=America/Toronto:20210818T130000
DTSTAMP:20210712T062316Z
CREATED:20210712T062316Z
LAST-MODIFIED:20210712T062316Z
UID:15425-1629288000-1629291600@scienceinboston.com
SUMMARY:Use Social Media to Promote Your Department/Center/Lab
DESCRIPTION:Learn how to use social media to publicize office initiatives\, programs and projects or engage and empower patients and/or colleagues by giving them an outlet for information and communication. Dr. Alex Towbin will share how he started using social media to publicize department projects and soon realized it could serve for promoting the entire department and increase its visibility and influence. Join this session to learn how to: \nList social media platforms to consider leveraging in your office.\nDiscuss benefits and best practices of using social media in health care and research.\nIdentify which team members to consult in your social media efforts. \nFacilitator: Alexander J. Towbin\, MD\, Professor of Radiology\, the Neil D. Johnson Chair of Radiology Informatics\, and Associate Chief of Radiology (Clinical Operations and Radiology Informatics) at Cincinnati Children’s Hospital. He is a recognized leader in pediatric radiology\, quality improvement\, and imaging informatics. He is a frequent speaker at meetings across the U.S. and the world speaking on a wide range of topics including the imaging of the pediatric liver tumors\, customer service\, operational planning\, quality improvement\, and social media.
URL:https://scienceinboston.com/event/use-social-media-to-promote-your-department-center-lab/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210818T120000
DTEND;TZID=America/Toronto:20210818T130000
DTSTAMP:20210712T062316Z
CREATED:20210712T062316Z
LAST-MODIFIED:20210712T062316Z
UID:27728-1629288000-1629291600@scienceinboston.com
SUMMARY:Use Social Media to Promote Your Department/Center/Lab
DESCRIPTION:Learn how to use social media to publicize office initiatives\, programs and projects or engage and empower patients and/or colleagues by giving them an outlet for information and communication. Dr. Alex Towbin will share how he started using social media to publicize department projects and soon realized it could serve for promoting the entire department and increase its visibility and influence. Join this session to learn how to: \nList social media platforms to consider leveraging in your office.\nDiscuss benefits and best practices of using social media in health care and research.\nIdentify which team members to consult in your social media efforts. \nFacilitator: Alexander J. Towbin\, MD\, Professor of Radiology\, the Neil D. Johnson Chair of Radiology Informatics\, and Associate Chief of Radiology (Clinical Operations and Radiology Informatics) at Cincinnati Children’s Hospital. He is a recognized leader in pediatric radiology\, quality improvement\, and imaging informatics. He is a frequent speaker at meetings across the U.S. and the world speaking on a wide range of topics including the imaging of the pediatric liver tumors\, customer service\, operational planning\, quality improvement\, and social media.
URL:https://scienceinboston.com/event/use-social-media-to-promote-your-department-center-lab-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210825T120000
DTEND;TZID=America/Toronto:20210825T123000
DTSTAMP:20210816T203833Z
CREATED:20210816T203833Z
LAST-MODIFIED:20210816T203833Z
UID:16000-1629892800-1629894600@scienceinboston.com
SUMMARY:RDM Experts Mini-Workshop: Tools for Reproducible Research
DESCRIPTION:Research Data Management (RDM) is the process of providing the appropriate labeling\, storage\, and access for data at all stages of a research project. Early and attentive management at each step of the data lifecycle will ensure the discoverability and longevity of your research. \nRDM Experts Mini-Workshops are free\, open sessions featuring short presentations or demos and provide an opportunity for discussion with the research data community. Sessions are held on Wednesdays at 12pm throughout the summer. Please register for the zoom link. \nJoin us for our 5th and final Summer Mini-Workshop with RDM Experts! \nTopic: Tools for Reproducible Research \nSpeakers: Radhika Khetani\, Ph.D.\, Research Scientist\, Training Director\, Bioinformatics Core\, Harvard T.H. Chan School of Public Health\nMeeta Mistry\, Ph.D.\, Research Scientist\, Senior Bioinformatics Analyst and Trainer\, Bioinformatics Core\, Harvard T.H. Chan School of Public Health
URL:https://scienceinboston.com/event/rdm-experts-mini-workshop-tools-for-reproducible-research/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210825T120000
DTEND;TZID=America/Toronto:20210825T123000
DTSTAMP:20210816T203833Z
CREATED:20210816T203833Z
LAST-MODIFIED:20210816T203833Z
UID:27739-1629892800-1629894600@scienceinboston.com
SUMMARY:RDM Experts Mini-Workshop: Tools for Reproducible Research
DESCRIPTION:Research Data Management (RDM) is the process of providing the appropriate labeling\, storage\, and access for data at all stages of a research project. Early and attentive management at each step of the data lifecycle will ensure the discoverability and longevity of your research. \nRDM Experts Mini-Workshops are free\, open sessions featuring short presentations or demos and provide an opportunity for discussion with the research data community. Sessions are held on Wednesdays at 12pm throughout the summer. Please register for the zoom link. \nJoin us for our 5th and final Summer Mini-Workshop with RDM Experts! \nTopic: Tools for Reproducible Research \nSpeakers: Radhika Khetani\, Ph.D.\, Research Scientist\, Training Director\, Bioinformatics Core\, Harvard T.H. Chan School of Public Health\nMeeta Mistry\, Ph.D.\, Research Scientist\, Senior Bioinformatics Analyst and Trainer\, Bioinformatics Core\, Harvard T.H. Chan School of Public Health
URL:https://scienceinboston.com/event/rdm-experts-mini-workshop-tools-for-reproducible-research-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210902T120000
DTEND;TZID=America/Toronto:20210902T120000
DTSTAMP:20210826T232312Z
CREATED:20210826T232312Z
LAST-MODIFIED:20210826T232312Z
UID:16167-1630584000-1630584000@scienceinboston.com
SUMMARY:Dana-Farber Targeted Protein Degradation Webinar Series: Dr. Stuart Schreiber
DESCRIPTION:30 years of Molecular Glues: Controlling cell circuitry in biology and medicine\n\nHost: Alyssa Verano \n\n\nDr. Schreiber’s research integrates chemical biology and human biology to advance both our understanding of chemistry and biology\, and the discovery of novel therapeutics. He is known for his use of small molecules to explore biology and medicine\, and for his role in the development of the field of chemical biology. With Jerry Crabtree in 1991\, his lab mapped the first membrane to nucleus signaling pathway (calcium–calcineurin–NFAT). His lab co-discovered mTOR in 1994 (simultaneously with Sabatini) and helped illuminate the mTOR-dependent nutrient-response signaling network. His lab discovered histone deacetylase (HDAC) and\, together with David Allis and Michael Grunstein in 1996\, the role of chromatin marks in gene expression. His work demonstrated for the first time that drugs can result from: 1) the targeting of protein kinases (sirolimus/mTOR) and protein phosphatases (sandimmune/ calcineurin); 2) gene regulation by chromatin-modifying enzymes (vorinostat/HDAC)\, 3) chemical inducers of proximity (CIPs) that activate cellular processes by enforced proximity (GVH Disease)\, and 4) targeting of the proteasome (bortezomib/proteasome). His research illustrated that many small molecules are bifunctional and act by inducing proximity of signaling proteins\, which he coined ‘molecular glues’. The discovery of molecular glues and development of chemical inducers of proximity led conceptually to the targeted degradation of proteins by small-molecule ‘PROTACs’. These efforts accelerated the development of many additional widely used drugs and more generally the field of chemical biology. \nSchreiber’s development of diversity-oriented synthesis has led to the discovery of many promising agents\, including a novel mechanism of action anti-malarial agent being developed in collaboration with the pharmaceutical company Eisai (Nature\, 2017). His most recent discovery revealed a novel cell state responsible for the ability of cancers to resist a wide range of therapies\, and a means to target the cancer therapy-resistant state (Nature\, 2017). His research has been reported in over 650 publications (H index = 147; Schreiber Publications) and recognized through numerous awards\, most recently the Arthur C. Cope Award and the Wolf Prize in Chemistry. \nFour new anti-cancer drugs that target proteins discovered in the Schreiber laboratory have been approved by the U.S. FDA: temsirolimus (Wyeth) and everolimus (Novartis)\, which target mTOR (discovered using rapamycin in 1994)\, for renal cancer\, and vorinostat (Merck) and romidepsin (Celgene)\, which target HDACs (HDAC1 discovered using trapoxin in 1996)\, for cutaneous T-cell lymphoma; in addition\, topical HDAC inhibitor remetinostat (Medivir\, PII clinical trials for CTCL)\, was conceived and synthesized in the Schreiber lab. A small-molecule molecular-glue drug (AP1903) reversed the effects of graft-versus-host disease in acute leukemia patients receiving hematopoietic stem cells engineered to express caspase-9 fused to a drug-responsive\, FKBP12-based dimerization domain (NEJM\, 2011). Proteins first shown by Schreiber to be targeted by a small molecule have been validated therapeutically by the FDA-approval process: tacrolimus (calcineurin/immu­nosuppres­sion/1994; Schreiber’s study of FK506) and bortezomib (proteasome/multiple myeloma/2003; Schreiber’s study of lactacystin). \nSchreiber extended chemical biology principles to medicine by participating in the founding of ten biotech companies\, beginning with Vertex Pharmaceuticals\, whose efforts have made cystic fibrosis a manageable disease. These companies have developed many novel therapeutic agents that are being tested in human clinical trials or used as FDA-approved drugs including: Vertex Pharmaceuticals (founded 1989: fosamprenavir/Lexiva; telaprevir/Incivek; ivacaftor/Kalydeco)\, ARIAD Pharmaceuticals (founded 1991: ponatinib/Iclusig; brigatinib/Alunbrig)\, ARIAD Gene Thera­peutics (founded 1994: ridaforolimus; AP1903)\, and Infinity Pharmaceuticals (founded 2001: reta­spimycin; duvelisib). Earlier stage chemical biology-based companies formed by Schreiber include: Forma Therapeutics\, H3 Biomedicines\, Jnana Therapeutics\, Kisbee Therapeutics\, Kojin Therapeutics and oNeir Therapeutics. In 2020\, Schreiber co-founded Scientists to Stop COVID-19\, a nonpartisan science-based group who advise policy makers in U.S. executive\, congressional and state governments\, as well as leaders in the sports and entertainment industries.
URL:https://scienceinboston.com/event/dana-farber-targeted-protein-degradation-webinar-series-dr-stuart-schreiber/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210902T120000
DTEND;TZID=America/Toronto:20210902T120000
DTSTAMP:20210826T232312Z
CREATED:20210826T232312Z
LAST-MODIFIED:20210826T232312Z
UID:27743-1630584000-1630584000@scienceinboston.com
SUMMARY:Dana-Farber Targeted Protein Degradation Webinar Series: Dr. Stuart Schreiber
DESCRIPTION:30 years of Molecular Glues: Controlling cell circuitry in biology and medicine\n\nHost: Alyssa Verano \n\n\nDr. Schreiber’s research integrates chemical biology and human biology to advance both our understanding of chemistry and biology\, and the discovery of novel therapeutics. He is known for his use of small molecules to explore biology and medicine\, and for his role in the development of the field of chemical biology. With Jerry Crabtree in 1991\, his lab mapped the first membrane to nucleus signaling pathway (calcium–calcineurin–NFAT). His lab co-discovered mTOR in 1994 (simultaneously with Sabatini) and helped illuminate the mTOR-dependent nutrient-response signaling network. His lab discovered histone deacetylase (HDAC) and\, together with David Allis and Michael Grunstein in 1996\, the role of chromatin marks in gene expression. His work demonstrated for the first time that drugs can result from: 1) the targeting of protein kinases (sirolimus/mTOR) and protein phosphatases (sandimmune/ calcineurin); 2) gene regulation by chromatin-modifying enzymes (vorinostat/HDAC)\, 3) chemical inducers of proximity (CIPs) that activate cellular processes by enforced proximity (GVH Disease)\, and 4) targeting of the proteasome (bortezomib/proteasome). His research illustrated that many small molecules are bifunctional and act by inducing proximity of signaling proteins\, which he coined ‘molecular glues’. The discovery of molecular glues and development of chemical inducers of proximity led conceptually to the targeted degradation of proteins by small-molecule ‘PROTACs’. These efforts accelerated the development of many additional widely used drugs and more generally the field of chemical biology. \nSchreiber’s development of diversity-oriented synthesis has led to the discovery of many promising agents\, including a novel mechanism of action anti-malarial agent being developed in collaboration with the pharmaceutical company Eisai (Nature\, 2017). His most recent discovery revealed a novel cell state responsible for the ability of cancers to resist a wide range of therapies\, and a means to target the cancer therapy-resistant state (Nature\, 2017). His research has been reported in over 650 publications (H index = 147; Schreiber Publications) and recognized through numerous awards\, most recently the Arthur C. Cope Award and the Wolf Prize in Chemistry. \nFour new anti-cancer drugs that target proteins discovered in the Schreiber laboratory have been approved by the U.S. FDA: temsirolimus (Wyeth) and everolimus (Novartis)\, which target mTOR (discovered using rapamycin in 1994)\, for renal cancer\, and vorinostat (Merck) and romidepsin (Celgene)\, which target HDACs (HDAC1 discovered using trapoxin in 1996)\, for cutaneous T-cell lymphoma; in addition\, topical HDAC inhibitor remetinostat (Medivir\, PII clinical trials for CTCL)\, was conceived and synthesized in the Schreiber lab. A small-molecule molecular-glue drug (AP1903) reversed the effects of graft-versus-host disease in acute leukemia patients receiving hematopoietic stem cells engineered to express caspase-9 fused to a drug-responsive\, FKBP12-based dimerization domain (NEJM\, 2011). Proteins first shown by Schreiber to be targeted by a small molecule have been validated therapeutically by the FDA-approval process: tacrolimus (calcineurin/immu­nosuppres­sion/1994; Schreiber’s study of FK506) and bortezomib (proteasome/multiple myeloma/2003; Schreiber’s study of lactacystin). \nSchreiber extended chemical biology principles to medicine by participating in the founding of ten biotech companies\, beginning with Vertex Pharmaceuticals\, whose efforts have made cystic fibrosis a manageable disease. These companies have developed many novel therapeutic agents that are being tested in human clinical trials or used as FDA-approved drugs including: Vertex Pharmaceuticals (founded 1989: fosamprenavir/Lexiva; telaprevir/Incivek; ivacaftor/Kalydeco)\, ARIAD Pharmaceuticals (founded 1991: ponatinib/Iclusig; brigatinib/Alunbrig)\, ARIAD Gene Thera­peutics (founded 1994: ridaforolimus; AP1903)\, and Infinity Pharmaceuticals (founded 2001: reta­spimycin; duvelisib). Earlier stage chemical biology-based companies formed by Schreiber include: Forma Therapeutics\, H3 Biomedicines\, Jnana Therapeutics\, Kisbee Therapeutics\, Kojin Therapeutics and oNeir Therapeutics. In 2020\, Schreiber co-founded Scientists to Stop COVID-19\, a nonpartisan science-based group who advise policy makers in U.S. executive\, congressional and state governments\, as well as leaders in the sports and entertainment industries.
URL:https://scienceinboston.com/event/dana-farber-targeted-protein-degradation-webinar-series-dr-stuart-schreiber-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210909T120000
DTEND;TZID=America/Toronto:20210909T130000
DTSTAMP:20210730T172903Z
CREATED:20210730T172903Z
LAST-MODIFIED:20210730T172903Z
UID:15775-1631188800-1631192400@scienceinboston.com
SUMMARY:Topics in Bioengineering: Khuluod Al Jamal\, Kings College London
DESCRIPTION:Topics in Bioengineering (TIB) is a student-led seminar series within the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS). Speakers are invited from academia\, government\, and industry to present cutting-edge research and topics within bioengineering. \nWith COVID-19 measures in place\, TIB has gone virtual: same great content\, different format. \nRegister now for our virtual seminars. Live closed captioning is available.
URL:https://scienceinboston.com/event/topics-in-bioengineering-khuluod-al-jamal-kings-college-london/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210909T120000
DTEND;TZID=America/Toronto:20210909T130000
DTSTAMP:20210730T172903Z
CREATED:20210730T172903Z
LAST-MODIFIED:20210730T172903Z
UID:27737-1631188800-1631192400@scienceinboston.com
SUMMARY:Topics in Bioengineering: Khuluod Al Jamal\, Kings College London
DESCRIPTION:Topics in Bioengineering (TIB) is a student-led seminar series within the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS). Speakers are invited from academia\, government\, and industry to present cutting-edge research and topics within bioengineering. \nWith COVID-19 measures in place\, TIB has gone virtual: same great content\, different format. \nRegister now for our virtual seminars. Live closed captioning is available.
URL:https://scienceinboston.com/event/topics-in-bioengineering-khuluod-al-jamal-kings-college-london-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210910T123000
DTEND;TZID=America/Toronto:20210910T140000
DTSTAMP:20210817T203721Z
CREATED:20210817T203721Z
LAST-MODIFIED:20210817T203721Z
UID:16034-1631277000-1631282400@scienceinboston.com
SUMMARY:A Fair Shot: Vaccine Patent Protections and Global Access
DESCRIPTION:Join us for the September Health Policy and Bioethics event. This session will explore the intersection of intellectual property protections\, facilitating global access to essential medicines\, and what we can learn from the handling of this pandemic going forward.
URL:https://scienceinboston.com/event/a-fair-shot-vaccine-patent-protections-and-global-access/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210910T123000
DTEND;TZID=America/Toronto:20210910T140000
DTSTAMP:20210817T203721Z
CREATED:20210817T203721Z
LAST-MODIFIED:20210817T203721Z
UID:27741-1631277000-1631282400@scienceinboston.com
SUMMARY:A Fair Shot: Vaccine Patent Protections and Global Access
DESCRIPTION:Join us for the September Health Policy and Bioethics event. This session will explore the intersection of intellectual property protections\, facilitating global access to essential medicines\, and what we can learn from the handling of this pandemic going forward.
URL:https://scienceinboston.com/event/a-fair-shot-vaccine-patent-protections-and-global-access-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210913T163000
DTEND;TZID=America/Toronto:20210913T174500
DTSTAMP:20210730T171803Z
CREATED:20210730T171803Z
LAST-MODIFIED:20210730T171803Z
UID:15772-1631550600-1631555100@scienceinboston.com
SUMMARY:The Next Normal: Global Health
DESCRIPTION:The COVID-19 pandemic highlighted the many ways in which we need to create better structures that generate population health and promote health equity. “The Next Normal” is a series of programs designed to take a moment to pause and ask\, as we emerge from the pandemic\, what we have learned and why\, in order to promote the health of all\, we cannot return to pre-pandemic normal. This program will explore the challenges and opportunities the COVID-19 pandemic presented related to global health\, reflecting on how we can use our learnings to build a better next normal.
URL:https://scienceinboston.com/event/the-next-normal-global-health/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210913T163000
DTEND;TZID=America/Toronto:20210913T174500
DTSTAMP:20210730T171803Z
CREATED:20210730T171803Z
LAST-MODIFIED:20210730T171803Z
UID:27736-1631550600-1631555100@scienceinboston.com
SUMMARY:The Next Normal: Global Health
DESCRIPTION:The COVID-19 pandemic highlighted the many ways in which we need to create better structures that generate population health and promote health equity. “The Next Normal” is a series of programs designed to take a moment to pause and ask\, as we emerge from the pandemic\, what we have learned and why\, in order to promote the health of all\, we cannot return to pre-pandemic normal. This program will explore the challenges and opportunities the COVID-19 pandemic presented related to global health\, reflecting on how we can use our learnings to build a better next normal.
URL:https://scienceinboston.com/event/the-next-normal-global-health-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210917T083000
DTEND;TZID=America/Toronto:20210917T160000
DTSTAMP:20210728T223914Z
CREATED:20210728T223914Z
LAST-MODIFIED:20210728T223914Z
UID:15748-1631867400-1631894400@scienceinboston.com
SUMMARY:Engineering the Next Wave of Immunotherapy
DESCRIPTION:The 19th Annual Koch Institute Summer Symposium will be held virtually on September 17\, 2021 and will focus on cancer immunotherapy. \nCancer immunotherapy has revolutionized the landscape of cancer treatment\, our thinking of tumor biology and clinical practice. Following the groundbreaking successes of checkpoint blockade therapy and CAR T cell therapy\, culminating in multiple FDA-approved treatments and the awarding of the 2018  Nobel Prize in Medicine to Jim Allison and Tasuku Honjo\, the field is currently at a critical juncture. \nWhile checkpoint blockade therapy has demonstrated that the immune system can be harnessed to fight cancer\,  the next generation of treatments will require us to understand what causes resistance in non-responders\, how this can be overcome\, and how these issues are best addressed clinically. Discussing these questions will be at the core of this symposium as we move towards our ultimate goal to increase the number of patients benefiting from immunotherapy. 
URL:https://scienceinboston.com/event/engineering-the-next-wave-of-immunotherapy/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210917T083000
DTEND;TZID=America/Toronto:20210917T160000
DTSTAMP:20210728T223914Z
CREATED:20210728T223914Z
LAST-MODIFIED:20210728T223914Z
UID:27735-1631867400-1631894400@scienceinboston.com
SUMMARY:Engineering the Next Wave of Immunotherapy
DESCRIPTION:The 19th Annual Koch Institute Summer Symposium will be held virtually on September 17\, 2021 and will focus on cancer immunotherapy. \nCancer immunotherapy has revolutionized the landscape of cancer treatment\, our thinking of tumor biology and clinical practice. Following the groundbreaking successes of checkpoint blockade therapy and CAR T cell therapy\, culminating in multiple FDA-approved treatments and the awarding of the 2018  Nobel Prize in Medicine to Jim Allison and Tasuku Honjo\, the field is currently at a critical juncture. \nWhile checkpoint blockade therapy has demonstrated that the immune system can be harnessed to fight cancer\,  the next generation of treatments will require us to understand what causes resistance in non-responders\, how this can be overcome\, and how these issues are best addressed clinically. Discussing these questions will be at the core of this symposium as we move towards our ultimate goal to increase the number of patients benefiting from immunotherapy. 
URL:https://scienceinboston.com/event/engineering-the-next-wave-of-immunotherapy-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210917T123000
DTEND;TZID=America/Toronto:20210917T140000
DTSTAMP:20210817T203855Z
CREATED:20210817T203855Z
LAST-MODIFIED:20210817T203855Z
UID:16037-1631881800-1631887200@scienceinboston.com
SUMMARY:Modifying Humans: Is Global Governance of Genome Editing Possible?
DESCRIPTION:Join us online for the September Ethics in Research and Biotechnology Consortium. In this interactive session\, Dr. Robin Lovell-Badge and Dr. Insoo Hyun will lead the audience through a discussion of the scientific\, ethical\, and policy considerations raised by efforts to successfully implement oversight and governance of genome editing
URL:https://scienceinboston.com/event/modifying-humans-is-global-governance-of-genome-editing-possible/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210917T123000
DTEND;TZID=America/Toronto:20210917T140000
DTSTAMP:20210817T203855Z
CREATED:20210817T203855Z
LAST-MODIFIED:20210817T203855Z
UID:27742-1631881800-1631887200@scienceinboston.com
SUMMARY:Modifying Humans: Is Global Governance of Genome Editing Possible?
DESCRIPTION:Join us online for the September Ethics in Research and Biotechnology Consortium. In this interactive session\, Dr. Robin Lovell-Badge and Dr. Insoo Hyun will lead the audience through a discussion of the scientific\, ethical\, and policy considerations raised by efforts to successfully implement oversight and governance of genome editing
URL:https://scienceinboston.com/event/modifying-humans-is-global-governance-of-genome-editing-possible-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210923T160000
DTEND;TZID=America/Toronto:20210923T170000
DTSTAMP:20210913T175052Z
CREATED:20210913T164148Z
LAST-MODIFIED:20210913T175052Z
UID:16408-1632412800-1632416400@scienceinboston.com
SUMMARY:Colloquium on the Brain and Cognition with Dr. Michelle Monje\, Stanford University
DESCRIPTION:Michelle Monje\, MD\, PhD\, is an associate professor of Neurology and Neurological Sciences at Stanford University. She received her M.D. and Ph.D. in Neuroscience from Stanford and completed her residency training in neurology at the Massachusetts General Hospital/Brigham and Women’s Hospital/Harvard Medical School Partners program\, and then returned to Stanford for a clinical fellowship in pediatric neuro-oncology and postdoctoral fellowship in developmental and cancer biology. Dr. Monje is recognized as an international leader in the pathophysiology of glioma\, especially diffuse intrinsic pontine glioma (DIPG)/H3K27M-mutated diffuse midline gliomas and a pioneer in the emerging field of Cancer Neuroscience. Her clinical focus is on childhood glial malignancies and cognitive impairment after childhood cancer therapy. Her laboratory studies neuron-glial interactions in health and disease\, with a particular focus on mechanisms and consequences of neuron-glial interactions in health\, glial dysfunction in cancer therapy-related cognitive impairment and neuron-glial interactions in malignant glioma. Together with these basic studies\, her research program has advanced preclinical studies of novel therapeutics for pediatric high-grade gliomas and cancer therapy-related cognitive impairment in order to translate new therapies to the clinic. She has led several of her discoveries from basic molecular work to clinical trials for children and young adults with brain tumors. \nThis event is being held virtually. Please click here to attend. \nHost: Li-Huei Tsai\nOrganizer: Brittany Greenough\nZoom: https://mit.zoom.us/j/99545907722
URL:https://scienceinboston.com/event/colloquium-on-the-brain-and-cognition-with-dr-michelle-monje-stanford-university/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210923T160000
DTEND;TZID=America/Toronto:20210923T170000
DTSTAMP:20210913T164148Z
CREATED:20210913T164148Z
LAST-MODIFIED:20210913T164148Z
UID:27746-1632412800-1632416400@scienceinboston.com
SUMMARY:Colloquium on the Brain and Cognition with Dr. Michelle Monje\, Stanford University
DESCRIPTION:Michelle Monje\, MD\, PhD\, is an associate professor of Neurology and Neurological Sciences at Stanford University. She received her M.D. and Ph.D. in Neuroscience from Stanford and completed her residency training in neurology at the Massachusetts General Hospital/Brigham and Women’s Hospital/Harvard Medical School Partners program\, and then returned to Stanford for a clinical fellowship in pediatric neuro-oncology and postdoctoral fellowship in developmental and cancer biology. Dr. Monje is recognized as an international leader in the pathophysiology of glioma\, especially diffuse intrinsic pontine glioma (DIPG)/H3K27M-mutated diffuse midline gliomas and a pioneer in the emerging field of Cancer Neuroscience. Her clinical focus is on childhood glial malignancies and cognitive impairment after childhood cancer therapy. Her laboratory studies neuron-glial interactions in health and disease\, with a particular focus on mechanisms and consequences of neuron-glial interactions in health\, glial dysfunction in cancer therapy-related cognitive impairment and neuron-glial interactions in malignant glioma. Together with these basic studies\, her research program has advanced preclinical studies of novel therapeutics for pediatric high-grade gliomas and cancer therapy-related cognitive impairment in order to translate new therapies to the clinic. She has led several of her discoveries from basic molecular work to clinical trials for children and young adults with brain tumors. \nThis event is being held virtually. Please click here to attend. \nHost: Li-Huei Tsai\nOrganizer: Brittany Greenough\nZoom: https://mit.zoom.us/j/99545907722
URL:https://scienceinboston.com/event/colloquium-on-the-brain-and-cognition-with-dr-michelle-monje-stanford-university-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210924T160000
DTEND;TZID=America/Toronto:20210924T170000
DTSTAMP:20210920T030507Z
CREATED:20210920T030507Z
LAST-MODIFIED:20210920T030507Z
UID:16508-1632499200-1632502800@scienceinboston.com
SUMMARY:MIT Microbiome Club General Body Meeting with Prof. Alvaro Sanchez
DESCRIPTION:Friday\, September 24th\n4:00 pm ET\nZoom\nPassword: Microbiome \nJoin us for the MIT Microbiome Club‘s first meeting of the year! \nThe first half of the meeting will be dedicated to discussing our club\, talking about what we accomplished last year\, and how you can get involved this year. We’re looking for many new people to join our board and help plan our amazing events! \nDuring the second half of the meeting\, Prof. Alvaro Sanchez\, an Associate Professor of Ecology and Evolutionary Biology at Yale University\, will talk to us about his work on quantitatively predicting microbial evolution\, ecology and behavior​. \nEvent will be virtual and free to the general public. Please RSVP on Eventbrite here​.
URL:https://scienceinboston.com/event/mit-microbiome-club-general-body-meeting-with-prof-alvaro-sanchez/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210924T160000
DTEND;TZID=America/Toronto:20210924T170000
DTSTAMP:20210920T030507Z
CREATED:20210920T030507Z
LAST-MODIFIED:20210920T030507Z
UID:27748-1632499200-1632502800@scienceinboston.com
SUMMARY:MIT Microbiome Club General Body Meeting with Prof. Alvaro Sanchez
DESCRIPTION:Friday\, September 24th\n4:00 pm ET\nZoom\nPassword: Microbiome \nJoin us for the MIT Microbiome Club‘s first meeting of the year! \nThe first half of the meeting will be dedicated to discussing our club\, talking about what we accomplished last year\, and how you can get involved this year. We’re looking for many new people to join our board and help plan our amazing events! \nDuring the second half of the meeting\, Prof. Alvaro Sanchez\, an Associate Professor of Ecology and Evolutionary Biology at Yale University\, will talk to us about his work on quantitatively predicting microbial evolution\, ecology and behavior​. \nEvent will be virtual and free to the general public. Please RSVP on Eventbrite here​.
URL:https://scienceinboston.com/event/mit-microbiome-club-general-body-meeting-with-prof-alvaro-sanchez-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210928T084500
DTEND;TZID=America/Toronto:20210928T123000
DTSTAMP:20210920T163544Z
CREATED:20210920T163544Z
LAST-MODIFIED:20210920T163544Z
UID:16564-1632818700-1632832200@scienceinboston.com
SUMMARY:Perturbations\, Therapeutics\, and Machine Learning
DESCRIPTION:The Jameel Clinic and Eric and Wendy Schmidt Center are partnering to organize a workshop on “Perturbations\, Therapeutics\, and Machine Learning”. The workshop will bring together speakers from multiple disciplines that are focused on taking on some of the toughest challenges at the interface of machine learning and biology. With our commitment to community building and open sharing of knowledge\, we would love it if you could join. \nThe workshop will be held on Tuesday\, September 28\, 2021 starting at 8:45 am EDT until 12:30 pm EDT. The workshop is an open event — feel free to invite your colleagues\, collaborators\, students\, and anyone who would benefit from the workshop.
URL:https://scienceinboston.com/event/perturbations-therapeutics-and-machine-learning/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210928T084500
DTEND;TZID=America/Toronto:20210928T123000
DTSTAMP:20210920T163544Z
CREATED:20210920T163544Z
LAST-MODIFIED:20210920T163544Z
UID:27749-1632818700-1632832200@scienceinboston.com
SUMMARY:Perturbations\, Therapeutics\, and Machine Learning
DESCRIPTION:The Jameel Clinic and Eric and Wendy Schmidt Center are partnering to organize a workshop on “Perturbations\, Therapeutics\, and Machine Learning”. The workshop will bring together speakers from multiple disciplines that are focused on taking on some of the toughest challenges at the interface of machine learning and biology. With our commitment to community building and open sharing of knowledge\, we would love it if you could join. \nThe workshop will be held on Tuesday\, September 28\, 2021 starting at 8:45 am EDT until 12:30 pm EDT. The workshop is an open event — feel free to invite your colleagues\, collaborators\, students\, and anyone who would benefit from the workshop.
URL:https://scienceinboston.com/event/perturbations-therapeutics-and-machine-learning-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210928T160000
DTEND;TZID=America/Toronto:20210928T170000
DTSTAMP:20210908T230710Z
CREATED:20210908T230710Z
LAST-MODIFIED:20210908T230710Z
UID:16327-1632844800-1632848400@scienceinboston.com
SUMMARY:The Genetics of Opioid Addiction: What We Know\, What We Are Learning
DESCRIPTION:The opioid epidemic is a pressing public health crisis. Opioid overdoses have become the leading cause of accidental death\, surpassing automobile accidents. This crisis has only been exacerbated during the COVID-19 pandemic with overdose deaths spiking up to 25% higher. Genetics is a major contributor to opioid use disorder\, and understanding the genes and gene variations involved could reveal critical aspects of the biology of addiction. \nWhitehead Institute Member Olivia Corradin and her lab are studying the genetics underlying opioid overdose. In this webinar\, she will describe the changes they have identified in the brain and how these changes converge on genes critical to the disorder.
URL:https://scienceinboston.com/event/the-genetics-of-opioid-addiction-what-we-know-what-we-are-learning/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Toronto:20210928T160000
DTEND;TZID=America/Toronto:20210928T170000
DTSTAMP:20210908T230710Z
CREATED:20210908T230710Z
LAST-MODIFIED:20210908T230710Z
UID:27745-1632844800-1632848400@scienceinboston.com
SUMMARY:The Genetics of Opioid Addiction: What We Know\, What We Are Learning
DESCRIPTION:The opioid epidemic is a pressing public health crisis. Opioid overdoses have become the leading cause of accidental death\, surpassing automobile accidents. This crisis has only been exacerbated during the COVID-19 pandemic with overdose deaths spiking up to 25% higher. Genetics is a major contributor to opioid use disorder\, and understanding the genes and gene variations involved could reveal critical aspects of the biology of addiction. \nWhitehead Institute Member Olivia Corradin and her lab are studying the genetics underlying opioid overdose. In this webinar\, she will describe the changes they have identified in the brain and how these changes converge on genes critical to the disorder.
URL:https://scienceinboston.com/event/the-genetics-of-opioid-addiction-what-we-know-what-we-are-learning-2/
LOCATION:Online
END:VEVENT
END:VCALENDAR